Eloxx Pharmaceuticals effects 1-for-40 reverse stock split to regain Nasdaq bid price compliance

Eloxx Pharmaceuticals, Inc.

Reverse split at 1-for-40 approved by shareholders on Nov 30, 2022; board set ratio same day.
Effective at 5:00 PM ET on Dec 1, 2022; split-adjusted trading begins Dec 2 under symbol ELOX.
Goal is to raise per-share price above Nasdaq's minimum $1 bid requirement and maintain listing.
Fractional shares will be cashed out at closing price on Nov 30; no fractional shares issued.
Proportionate adjustments made to outstanding equity awards, warrants, and equity plans.

item 3.03 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Eloxx Pharmaceuticals, Inc.: Implemented a 1-for-40 reverse stock split by filing a Certificate of Amendment to the Certificate of Incorporation (effective 2022-12-01).

Change: charter amendment
Effective: 2022-12-01

Exact text from the filing

On December 1, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment (the “ Certificate of Amendment ”) with the Secretary of State of the State of Delaware to amend the Company’s Certificate of Incorporation to effect the Reverse Stock Split. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on December 1, 2022.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-123704

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.